NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 36 pharmaceutical companies such as RISING, EPIC PHARMA LLC, CHATTEM SANOFI and others. It is marketed under 7 brand names, including TRIAMCINOLONE ACETONIDE, NASACORT ALLERGY 24 HOUR, TRIDERM and others. Available in 11 different strengths, such as 0.1%, 0.025%, 0.055MG/SPRAY and others, and administered through 9 routes including PASTE;DENTAL, LOTION;TOPICAL, SPRAY, METERED;NASAL and others.
API availability: Loading API feasibility...
Licensing: 36 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"82597","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"XIPERE","family_id":"bf873845064045f1a526","publication_number":"US8636713B2","cleaned_patent_number":"8636713","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-05-02","publication_date":"2014-01-28","legal_status":"Granted"} | US8636713B2 | 28 Jan, 2014 | Granted | 02 May, 2027 | |
| {"application_id":"62863","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"TRIESENCE","family_id":"e19fc89bad494528af27","publication_number":"US8211880B2","cleaned_patent_number":"8211880","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-10","publication_date":"2012-07-03","legal_status":"Granted"} | US8211880B2 | 03 Jul, 2012 | Granted | 10 Mar, 2029 | |
| {"application_id":"62882","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"TRIESENCE","family_id":"e19fc89bad494528af27","publication_number":"US8128960B2","cleaned_patent_number":"8128960","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-12-17","publication_date":"2012-03-06","legal_status":"Granted"} | US8128960B2 Formulation | 06 Mar, 2012 | Granted | 17 Dec, 2029 | |
| {"application_id":"57499","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"ZILRETTA","family_id":"3af114c7e0b946dba8e8","publication_number":"US8828440B2","cleaned_patent_number":"8828440","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-08-04","publication_date":"2014-09-09","legal_status":"Granted"} | US8828440B2 Formulation | 09 Sep, 2014 | Granted | 04 Aug, 2031 | |
| {"application_id":"57458","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"ZILRETTA","family_id":"3af114c7e0b946dba8e8","publication_number":"US9555048B2","cleaned_patent_number":"9555048","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-08-04","publication_date":"2017-01-31","legal_status":"Granted"} | US9555048B2 | 31 Jan, 2017 | Granted | 04 Aug, 2031 | |
| {"application_id":"82663","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"XIPERE","family_id":"4728353d4cf34241b89c","publication_number":"US9636332B2","cleaned_patent_number":"9636332","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-11-08","publication_date":"2017-05-02","legal_status":"Granted"} | US9636332B2 | 02 May, 2017 | Granted | 08 Nov, 2033 | |
| {"application_id":"82629","ingredient":"TRIAMCINOLONE ACETONIDE","trade_name":"XIPERE","family_id":"6ebf96fee5754ecc952c","publication_number":"US9937075B2","cleaned_patent_number":"9937075","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-05-02","publication_date":"2018-04-10","legal_status":"Granted"} | US9937075B2 Formulation | 10 Apr, 2018 | Granted | 02 May, 2034 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Triamcinolone Acetonide
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.